Chronic Plaque Psoriasis Pipeline-Review-2021

Psoriasis is a type of skin disease. It comes in various forms, but the most common is plaque psoriasis. The signs and symptoms of plaques include red patches covered with a whitish buildup of dead skins cells known as scale. They usually occurs on knees, elbows, scalp, and lower back. Plaques mainly cause itching or it hurts. Most types of plaque psoriasis are labelled as 'small plaque' or 'large plaque' psoriasis. The plaques may be localized (e.g. to knees and elbows) or generalised (including trunk, scalp, and limbs).

Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Chronic Plaque Psoriasis. For instance, in March 2020, a late-stage biopharmaceutical company “Arcutis Biotherapeutics, Inc.” which is focused on manufacturing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, declared the inclusion of children in on-going pivotal phase 3 clinical trials estimating topical Roflumilast (ARQ-151) as a significant once daily topical treatment for plaque psoriasis.

Approximately 80% of pipeline drugs for Chronic Plaque Psoriasis are in phase 2 and 3 clinical stage. In U.S, psoriasis infects 0.6 to 4.8 percent of the population every year, and approximately 30 percent of patients affected have a first-degree associated with the disease.

Report Description

The report on Chronic Plaque Psoriasis- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Chronic Plaque Psoriasis. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Chronic Plaque Psoriasis (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences
• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies

• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline